Get started
Author

M.L. Shiffman

Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection
2015 · Mark S. Sulkowski, Hugo E. Vargas, et al. · Gastroenterology · 177
PDF
Review article: management of patients with chronic hepatitis C virus infection and ‘normal’ alanine aminotransferase activity
2006 · S. ZEUZEM, A. ALBERTI, et al. · Alimentary Pharmacology & Therapeutics · 48
PDF
Sofosbuvir/Velpatasvir in Combination with Ribavirin for 24 Weeks is Effective Retreatment for Patients who failed Prior NS5A Containing DAA Regimens: Results of the GS-US-342-1553 Study
2016 · E.J. Gane, M.L. Shiffman, et al. · Journal of Hepatology · 32
734 Peginterferon alpha-2a (PEGASYS) plus ribavirin (COPEGUS) for 16 or 24 weeks in patients with HCV genotype 2 OR 3. Final results of the accelerate trial
2006 · M.L. Shiffman, S. Pappas, et al. · Journal of Hepatology · 28
PDF
SOF/VEL/VOX for 8 or 12 weeks is well tolerated and results in high SVR12 rates in patients receiving opioid substitution therapy
2017 · J. Grebely, I.M. Jacobson, et al. · Journal of Hepatology · 18
1177 RAPID AND SUSTAINED ACHIEVEMENT OF UNDETECTABLE HCV RNA DURING TREATMENT WITH RITONAVIR-BOOSTED DANOPREVIR/PEG-IFNa-2A/RBV IN HCV GENOTYPE 1 OR 4 PATIENTS: DAUPHINE WEEK 12 INTERIM ANALYSIS
2012 · G. Everson, C. Cooper, et al. · Journal of Hepatology · 18
4 Svr With Telaprevir, Peginterferon Alfa-2a and Ribavirin in Hcv Patients With Well-characterized Prior Null Response, Partial Response, Viral Breakthrough or Relapse After Pr
2010 · T. Berg, J.G. McHutchison, et al. · Journal of Hepatology · 17
744 Sustained virologic response (SVR) to interferon-alpha-2b +/- ribavirin therapy at 6 months reliably predicts long-term clearance of HCV at 5-year follow-up
2006 · J.G. McHutchison, M.L. Shiffman, et al. · Journal of Hepatology · 16
Percutaneous liver biopsy in adult haemophiliacs with hepatitis C virus: safety of outpatient procedure and impact of human immunodeficiency virus coinfection on the spectrum of liver disease
2007 · R. K. STERLING, C. D. LYONS, et al. · Haemophilia · 15
100% SVR4 with ABT-493 and ABT-530 with or without Ribavirin in Treatment-Naïve HCV Genotype 3-Infected Patients with Cirrhosis
2016 · P.Y. Kwo, D.L. Wyles, et al. · Journal of Hepatology · 14
64 Gs-5885 + Gs-9451 + Peginterferon and Ribavirin (pr) for Six or Twelve Weeks Achieves High Svr12 Rates in Treatment-naïve Genotype 1 Il28b Cc Patients
2013 · A. Thompson, S. Han, et al. · Journal of Hepatology · 14
2006 Gi-5005 Therapeutic Vaccine Plus Peg-ifn/ribavirin Significantly Improves Virologic Response and Alt Normalization at End-of-treatment and Improves Svr24 Compared to Peg-ifn/ribavirin in Genotype-1 Chronic Hcv Patients
2010 · I.M. Jacobson, J.G. McHutchison, et al. · Journal of Hepatology · 13
503 Durability of HBeAg seroconversion following adefovir dipivoxil treatment for chronic hepatitis B (CHB)
2006 · T.T. Chang, M.L. Shiffman, et al. · Journal of Hepatology · 12
PDF
505 The influence of cumulative exposure to combination peginterferon alfa-2A (40 KD) (Pegasys) and ribavirin on sustained virological response (SVR) rates in patients with genotype 1 chronic hepatitis C
2004 · K.R. Reddy, M.W. Fried, et al. · Journal of Hepatology · 10
144 Suppression of Serum Hcv Rna Levels During Maintenance Peginterferon (pegifn) Alfa-2a Therapy and Clinical Outcomes in the Halt-c Trial
2008 · M.L. Shiffman, C. Morishima, et al. · Journal of Hepatology · 9
1188 Phase 2 Randomized, Double-blind, Placebo-controlled Study of Nitazoxanide With Peginterferon Alfa-2a and Ribavirin in Nonresponders (nr) With Chronic Hepatitis C Genotype 1: Final Report
2010 · M.L. Shiffman, A. Ahmed, et al. · Journal of Hepatology · 8
PDF
835 Time to Hcvrna Undetectability Supersedes Baseline Factors in Predicting Svr in Patients With Hcv Genotype 1
2008 · M.L. Shiffman, R.T. Chung, et al. · Journal of Hepatology · 8
PDF
2001 Phase 2 Randomized, Double-blind, Placebo-controlled Study of Nitazoxanide Plus Peginterferon and Ribavirin in Hcv Genotype 1 Naive Patients: Week 12 Sustained Virologic Response Rate
2010 · B.R. Bacon, M.L. Shiffman, et al. · Journal of Hepatology · 7
503 Early prediction of sustained virological response (SVR) during treatment with peginterferon alfa-2A (40KD) (PEGASYS®) plus ribavirin (RBV) (COPEGUS®) in patients with chronic hepatitis C (CHC) and persistently normal alanine aminotransferase (ALT) levels
2004 · P.J. Pockros, M. Diago, et al. · Journal of Hepatology · 7
Treatment of patients with chronic hepatitis C (CHC) with peginterferon alfa-2a (40KD) (Pegasys) alone or in combination with ribavirin (copegus) results in long-lasting sustained virological response
2003 · M. Swain, M.-Y. Lai, et al. · Journal of Hepatology · 7
Durability of HBeAg seroconversion following adefovir dipivoxil treatment for chronic hepatitis B
2006 · Ting‐Tsung Chang, M.L. Shiffman, et al. · Journal of Hepatology · 6
627 Gi-5005 Immunotherapy Plus Peg-ifn/ribavirin Versus Peg-ifn/ribavirin in Genotype 1 Chronic Hcv Subjects; Preliminary Phase 2 Evr Analyses
2009 · E.J. Lawitz, T.D. Boyer, et al. · Journal of Hepatology · 5
499 The impact of sustained virological response (SVR) on health-related quality of life (HRQL) in patients with chronic hepatitis C (CHC) and persistently normal ALT levels (PNALT) treated with peginterferon alfa-2A (PEGASYS®) and ribavirin (COPEGUS®)
2004 · C. O'Brien, N. Wintfeld, et al. · Journal of Hepatology · 5
O163 Turquoise-ii: Svr12 Rates of 92–96% in 380 Hepatitis C Virus Genotype 1-infected Adults With Compensated Cirrhosis Treated With Abt-450/r/abt-267 and Abt-333 Plus Ribavirin (3d+rbv)
2014 · F. Poordad, C. Hezode, et al. · Journal of Hepatology · 4
792 48 WEEKS OF PEGINTERFERON alfa-2a/RIBAVIRIN IMPROVES SVR24 AND DECREASES RELAPSE ACROSS HCV GENOTYPE 2/3 PATIENT SUBGROUPS NOT ACHIEVING A RAPID VIROLOGICAL RESPONSE: N-CORE STUDY
2013 · T. Berg, M.L. Shiffman, et al. · Journal of Hepatology · 4
Works count: 47
Citation count: 521
H-index: 12
I10-index: 14
Year
Topic
Type